Results 181 to 190 of about 45,247 (265)

Cyclic peptides discriminate BCL-2 and its clinical mutants from BCL-XL by engaging a single-residue discrepancy

Nature Communications
Overexpressed pro-survival B-cell lymphoma-2 (BCL-2) family proteins BCL-2 and BCL-XL can render tumor cells malignant. Leukemia drug venetoclax is currently the only approved selective BCL-2 inhibitor. However, its application has led to an emergence of
Fengwei Li, Junjie Liu, Chao Liu, Ziyan Liu, Xiangda Peng, Yinyue Huang, Xiaoyu Chen, Xiangnan Sun, Sen Wang, Wei Chen, Dan Xiong, Xiaotong Diao, Sheng Wang, Jingjing Zhuang, Chuanliu Wu, Dalei Wu   +15 more
doaj   +1 more source

Targeting SHP‐1‐Mediated Inhibition of STAT3 and ERK Signalling Pathways Rescues the Hyporesponsiveness of MHC‐I‐Deficient NK‐92MI

Cell Proliferation, EarlyView.
B2M knockout (KO) represents a crucial strategy for generating universal NK‐92MI cell products. This approach results in increased phosphorylation of SHP‐1 and inhibited phosphorylation of STAT3 and ERK, which ultimately affect their cytotoxic capabilities. SHP‐1 KO facilitates the restoration of cytotoxic function in B2M KO NK‐92MI cells.
Kuo Yu, Xiaolong Liu, Guangyuan Wu, Zhongyao An, Xin Wang, Yang Liu, Hailong Wang, Mingli Huang, Linlin Zhao, Ce Shi, Xin Sun, Lu Xu, Sen Qi, Xin Zhang, Yueqiu Teng, Song Guo Zheng, Zhiren Zhang, Zhenkun Wang   +17 more
wiley   +1 more source

Rac2 Stimulates Akt Activation Affecting BAD/Bcl-XL Expression while Mediating Survival and Actin Function in Primary Mast Cells [PDF]

, 2000
Feng‐Chun Yang, Reuben Kapur, Alastair J. King, Tao Wen, Chaekyun Kim, Jovencio Borneo, Robert Breese, Mark S. Marshall, Mary C. Dinauer, David A. Williams   +9 more
openalex   +1 more source

Tumour Cell Size Control and Its Impact on Tumour Cell Function

Cell Proliferation, EarlyView.
The regulatory mechanism of the size of tumour cells and its impact on the functions of tumour cells, as well as a summary of potential therapeutic targets for the corresponding mechanisms. ABSTRACT Cell size is an important component of cell morphological characteristics.
Min Zhou, Mei Zhou, Yang Jin
wiley   +1 more source

Bcl-xL regulates radiation-induced ferroptosis through chaperone-mediated autophagy of GPX4 in tumor cells

Radiation Medicine and Protection
Objective: To investigate the role and the molecular mechanisms of apoptotic signaling in ferroptosis to regulate tumor radiosensitivity. Methods: Reactive oxygen species (ROS) and lipid peroxide levels were detected in Mouse embryonic fibroblasts(MEFs ...
Jing Han, Ruru Wang, Bin Chen, Feng Xu, Liangchen Wei, An Xu, Lijun Wu, Guoping Zhao   +7 more
doaj  

Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts

Scientific Reports
Triple negative breast cancers (TNBC) present a poor prognosis primarily due to their resistance to chemotherapy. This resistance is known to be associated with elevated expression of certain anti-apoptotic members within the proteins of the BCL-2 family
Lisa Nocquet, Julie Roul, Chloé C. Lefebvre, Laurine Duarte, Mario Campone, Philippe P. Juin, Frédérique Souazé   +6 more
doaj   +1 more source

Expression of Bcl-XL Restores Cell Survival, but Not Proliferation and Effector Differentiation, in Cd28-Deficient T Lymphocytes [PDF]

, 2000
Astrid M. Dahl, Christoph Klein, Pietro G. Andres, Cheryl A. London, Michael P. Lodge, Richard C. Mulligan, Abul K. Abbas   +6 more
openalex   +1 more source

Extracellular vesicles in multiple myeloma: pathogenesis and therapeutic application

The FEBS Journal, EarlyView.
Multiple myeloma is characterised by the clonal proliferation of plasma cells in the bone marrow. Extracellular vesicles (EVs) are a key component of cell‐to‐cell communication within the bone marrow microenvironment, promoting tumour growth, bone remodelling, immune modulation, angiogenesis and therapeutic resistance.
Chloe Wylie, Rebecca Rowan, Dessi Malinova, Lisa Crawford   +3 more
wiley   +1 more source

The G protein‐coupled receptor GPR89A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells

The FEBS Journal, EarlyView.
A genome‐wide CRISPR‐Cas9‐based genetic screen in cisplatin‐resistant NSCLC cells revealed 63 potential candidate genes for overcoming cisplatin resistance, including GPR89A. GPR89A, localised in the Golgi, modulates voltage‐gated anion channel activity and is involved in intracellular pH reduction.
Hale Guler Kara, Eda Dogan, Vildan Bozok, Cagdas Aktan, Ece Cakiroglu, Zuhal Eroglu, Duygu Aygunes Jafari, Kemal Sami Korkmaz, Serif Senturk, Buket Kosova   +9 more
wiley   +1 more source

Exploratory Advanced Radiotherapies for Ameloblastoma and Ameloblastic Carcinoma—A Concise Review

Oral Diseases, EarlyView.
ABSTRACT Objective Ameloblastoma is an aggressively growing odontogenic tumor with substantial management challenges and a high recurrence rate. Surgical resection is the treatment of choice for ameloblastoma, but adjuvant therapies like radiation have been explored in cases where surgery is not clinically advisable and the tumor is inoperable.
Heba Turkstani, Afrah Alfaifi, Sunday O. Akintoye   +2 more
wiley   +1 more source